title: Conference report: "Functional Glycomics in HIV Type 1 Vaccine Design" workshop report, Bethesda, Maryland, April 30-May 1, 2012.
abstract: A vital part of the renewed hope for a vaccine against the human immunodeficiency virus (HIV-1) is based on recent studies that have highlighted major sites of HIV-1 vulnerability that could be effectively targeted by a preventive vaccine. One of these potential vulnerabilities includes the dense cluster of carbohydrates surrounding HIV-1's envelope glycoproteins gp120 and gp41, typically referred to as the "glycan shield." Recent data from several laboratories have shown that glycans on the HIV-1 envelope form key epitopes for broadly neutralizing antibodies (bNAb). Moreover, HIV-1 envelope glycans play an important role in viral transmission, antigenicity, and immunogenicity. The recent availability of novel tools and technologies has now allowed investigators to leverage glycomic structure-function relationships in the design of candidate HIV-1 vaccines. Additionally, glycans modulate the immune response, playing an essential role in Fc receptor and complement activity. To promote cross-disciplinary collaboration and promote synergistic HIV-1- glycomics research, the National Institutes of Health (NIH) cosponsored and convened a 1.5-day workshop entitled "Functional Glycomics in HIV-1 Vaccine Design." The meeting focused on the role of glycan interactions with neutralizing antibodies, the influence of immunoglobulin G (IgG) Fc receptor glycosylation, newly available glycomics technologies, and how new information on the role of glycans could be applied in HIV-1 immunogen design strategies. This report summarizes the discussions of this workshop.
authors.affiliation: 1 Preclinical Research and Development Branch, Division of AIDS, U.S. National Institute of Allergy and Infectious Diseases , Bethesda, Maryland.
authors.forename: Angela
authors.initials: A
authors.lastname: Malaspina
authors.forename: Brenda S
authors.initials: BS
authors.lastname: Collins
authors.forename: Anne
authors.initials: A
authors.lastname: Dell
authors.forename: Galit
authors.initials: G
authors.lastname: Alter
authors.forename: Thandi M
authors.initials: TM
authors.lastname: Onami
mesh_terms: D016915:AIDS Vaccines / Q000276:immunology* / Q000302:isolation & purification*; D054794:Glycomics; D015699:HIV Envelope Protein gp120 / Q000737:chemistry / Q000276:immunology; D015700:HIV Envelope Protein gp41 / Q000737:chemistry / Q000276:immunology; D015658:HIV Infections / Q000517:prevention & control*; D015497:HIV-1 / Q000737:chemistry* / Q000276:immunology*; D006801:Humans
chemical_list: D016915:AIDS Vaccines; D015699:HIV Envelope Protein gp120; D015700:HIV Envelope Protein gp41; C514793:gp120 protein, Human immunodeficiency virus 1; C514787:gp41 protein, Human immunodeficiency virus 1